#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	5404	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2329	453.7	0	.	n	.	0	C1450T	SNP	1450	1450	C	1667	1667	T	573	T	363	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	5404	16S	1529	1529	99.93	16S.l15.c4.ctg.1	2329	453.7	1	SNP	n	C1184T	0	.	.	1184	1184	C	1401	1401	C	693	C	445	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	10298	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3582	549.2	0	.	n	.	0	G1337A	SNP	1337	1337	G	1809	1809	A	579	A,C	381,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	10298	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3582	549.2	0	.	n	.	0	T1971C	SNP	1971	1971	T	2443	2443	C	497	C	340	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	10298	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3582	549.2	1	SNP	n	A2045G	0	.	.	2045	2045	A	2517	2517	A	542	A	350	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	10298	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3582	549.2	1	SNP	n	C2597T	0	.	.	2597	2597	C	3069	3069	C	602	C	409	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_O_01412c	folP.WHO_O_01412c	1	1	27	494	folP	855	855	100.0	folP.l6.c4.ctg.1	1819	53.6	1	SNP	p	R229S	1	.	.	685	687	AGC	1084	1086	AGC	58;59;58	A;G;C	41;43;41	folP.WHO_O_01412c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	1328	gyrA	2751	2751	99.96	gyrA.l15.c17.ctg.1	3475	75.6	1	SNP	p	S91F	1	.	.	271	273	TTC	684	686	TTC	102;102;102	T;T;C,T,A	66;65;64,1,1	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	1328	gyrA	2751	2751	99.96	gyrA.l15.c17.ctg.1	3475	75.6	1	SNP	p	D95G	1	.	.	283	285	GGC	696	698	GGC	109;109;109	G;G;C	69;69;67	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	1328	gyrA	2751	2751	99.96	gyrA.l15.c17.ctg.1	3475	75.6	1	SNP	p	G95N	0	.	.	283	285	GGC	696	698	GGC	109;109;109	G;G;C	69;69;67	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	27	416	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1265	68.9	1	SNP	p	G45D	0	.	.	133	135	GGC	383	385	GGC	122;122;122	G;G;C	75;75;76	mtrR.WHO_O_01438:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	252	mtrR_promoter	250	250	99.6	mtrR_promoter.l6.c4.ctg.1	835	52.5	0	.	n	.	0	A197.	DEL	197	197	A	499	499	A	99	A	65	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	1086	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2992	71.3	0	.	p	.	0	I384V	NONSYN	1150	1152	ATC	1579	1581	GTC	76;76;76	G;T;C	50;51;50	.	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	1086	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2992	71.3	1	SNP	p	D86N	0	.	.	256	258	GAC	685	687	GAC	93;94;96	G;A;C	62;53;64	parC.WHO_V_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	1086	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2992	71.3	1	SNP	p	R87I	0	.	.	259	261	CGT	688	690	CGT	96;96;100	C;G;T	60;60;64	parC.WHO_V_00204c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	1086	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2992	71.3	1	SNP	p	R87W	0	.	.	259	261	CGT	688	690	CGT	96;96;100	C;G;T	60;60;64	parC.WHO_V_00204c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	1086	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2992	71.3	1	SNP	p	S87R	1	.	.	259	261	CGT	688	690	CGT	96;96;100	C;G;T	60;60;64	parC.WHO_V_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_V_00204c	parC.WHO_V_00204c	1	1	539	1086	parC	2304	2304	99.87	parC.l15.c4.ctg.1	2992	71.3	1	SNP	p	S88P	0	.	.	262	264	TCC	691	693	TCC	100;102;102	T;C,T;C	64;68,1;70	parC.WHO_V_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	890	parE	1986	1986	99.95	parE.l6.c30.ctg.1	3015	59.8	0	.	p	.	0	R340C	NONSYN	1018	1020	CGC	1471	1473	TGC	71;71;72	T;G,A;C	50;49,1;50	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	890	parE	1986	1986	99.95	parE.l6.c30.ctg.1	3015	59.8	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1681	1683	GGC	69;69;69	G;G;C,G	45;45;42,1	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.12.001	penA.12.001	1	1	27	1068	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2498	82.6	1	SNP	p	A311V	0	.	.	931	933	GCA	1331	1333	GCA	112;112;112	G;C;A	80;80;81	penA.12.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	1068	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2498	82.6	1	SNP	p	I312M	0	.	.	934	936	ATC	1334	1336	ATC	116;116;116	A;T;C	81;83;83	penA.12.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	1068	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2498	82.6	1	SNP	p	V316T	0	.	.	946	948	GTG	1346	1348	GTG	120;122;122	G,T;T;G	84,1;86;86	penA.12.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	1068	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2498	82.6	1	SNP	p	V316P	0	.	.	946	948	GTG	1346	1348	GTG	120;122;122	G,T;T;G	84,1;86;86	penA.12.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	1068	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2498	82.6	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1850	1852	ACC	88;88;87	A;C;C	61;63;63	penA.12.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	1068	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2498	82.6	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1904	1906	GCG	75;70;69	G;C;G	57;50;51	penA.12.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	1068	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2498	82.6	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1904	1906	GCG	75;70;69	G;C;G	57;50;51	penA.12.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	1068	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2498	82.6	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2027	2029	GGC	71;72;73	G,C;G;C	51,1;54;53	penA.12.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	1068	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2498	82.6	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2036	2038	GGC	64;65;64	G;G,T;C,G	49;49,1;45,1	penA.12.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.12.001	penA.12.001	1	1	27	1068	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2498	82.6	1	SNP	p	P552S	1	.	.	1654	1656	TCG	2054	2056	TCG	67;67;67	T,G;C;G	38,4;44;45	penA.12.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	1954	ponA	2397	2397	100.0	ponA.l15.c17.ctg.1	3225	113.9	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1672	1674	CCG	72;72;72	C,T,G;C,A;G	52,1,1;54,1;52	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	572	porA	1146	1146	99.56	porA.l15.c4.ctg.1	1785	63.3	0	.	p	.	0	M83fs	FSHIFT	247	247	A	513	513	C	50	C	30	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	46	porB1a	984	112	91.96	porB1a.l15.c4.ctg.1	342	17.4	0	.	p	.	0	M18T	NONSYN	52	54	ATG	255	257	ACG	23;23;23	A;C;G	15;16;15	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	46	porB1a	984	112	91.96	porB1a.l15.c4.ctg.1	342	17.4	0	.	p	.	0	E32Q	NONSYN	94	96	GAA	297	299	CAA	10;10;10	C;A;A	8;8;8	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	46	porB1a	984	112	91.96	porB1a.l15.c4.ctg.1	342	17.4	0	.	p	.	0	S34Y	NONSYN	100	102	TCC	303	305	TAC	8;8;8	T;A;C	6;6;6	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	660	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	1708	75.7	0	.	p	.	0	N38E	NONSYN	112	114	AAT	476	478	GAA	115;113;113	G;A,G;A	75;72,1;73	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	660	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	1708	75.7	0	.	p	.	0	N134D	NONSYN	400	402	AAT	764	766	GAT	82;86;86	G;A;T,G	60;61;60,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	660	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	1708	75.7	0	.	p	.	0	P175S	NONSYN	523	525	CCA	887	889	TCA	103;101;101	T,G;C;A	67,1;68;68	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	660	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	1708	75.7	0	.	p	.	0	A218V	NONSYN	652	654	GCC	1016	1018	GTC	90;93;93	G;T;C	61;62;62	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	660	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	1708	75.7	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1346	1348	GCA	87;85;85	G;C;A	62;61;61	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	660	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	1708	75.7	1	SNP	p	G120K	1	.	.	358	360	AAG	722	724	AAG	93;93;92	A;A;G	66;65;67	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	660	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	1708	75.7	1	SNP	p	A121D	1	.	.	361	363	GAC	725	727	GAC	92;92;94	G;A;C	67;66;67	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	660	porB1b	1047	1047	99.33	porB1b.l15.c4.ctg.1	1708	75.7	1	SNP	p	D121N	0	.	.	361	363	GAC	725	727	GAC	92;92;94	G;A;C	67;66;67	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	1	0	272	30	porB3	990	116	92.24	porB3.l6.c4.ctg.1	584	6.7	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	2116	rpoB	4179	4179	100.0	rpoB.l6.c4.ctg.1	4894	84.3	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2007	2009	AAT	94;94;95	A;A;T	62;62;63	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	164	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1278	26.6	1	SNP	p	V57M	1	.	.	169	171	ATG	665	667	ATG	59;56;58	A;T;G	38;37;38	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
